Rufus Herve Bacote

Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID

Retrieved on: 
Monday, December 13, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, Other Health, Forward-looking statement, HERV-W, COVID, Technology, Symptoms of COVID-19, Company, FOPH, HIV disease progression rates, Severe acute respiratory syndrome coronavirus 2, Clinical trial, Euronext Paris, Genome, Brain, Public health, Association, Degenerative disease, Industry, Multiple sclerosis, COVID-19, Lancet, Rufus Herve Bacote, CEO, Swiss Federal Institute of Aquatic Science and Technology, Patient, Lymphocyte, Endothelium, Patent, Neurodegeneration, Alzheimer's disease, Blood, Long COVID, Pediatric acute-onset neuropsychiatric syndrome, Parkinson's disease, Lists of diseases, Pharmaceutical industry, Vaccine, Medical imaging, W-ENV and COVID-19, GeNeuro, W-ENV AND COVID-19, GENEURO

"We are extremely grateful for this funding from the FOPH, which will allow us to test GeNeuro's treatment for the neuropsychiatric forms of Long-COVID," said Jess Martin-Garcia, CEO of GeNeuro.

Key Points: 
  • "We are extremely grateful for this funding from the FOPH, which will allow us to test GeNeuro's treatment for the neuropsychiatric forms of Long-COVID," said Jess Martin-Garcia, CEO of GeNeuro.
  • Our approach is one of the first concrete leads to explain these problems, and also potentially to treat them with temelimab, GeNeuro's anti-W-ENV antibody."
  • This may allow early identification and treatment of patients who could benefit from anti-W-ENV therapy with temelimab.
  • Based in Geneva, Switzerland, and with an R&D center in Lyon, France, GeNeuro holds the rights to 17 patent families that protect its technology.

GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID

Retrieved on: 
Friday, September 24, 2021
Research, Genetics, Clinical Trials, Biotechnology, Health, University, Pharmaceutical, Science, Education, Blood, International Center, Northwestern University, Patent, Lists of diseases, Research, Endothelium, Degenerative disease, Euronext Paris, Pediatric acute-onset neuropsychiatric syndrome, HERV-W, DNA, Patient, COVID, Lymphocyte, Disease, Leadership, COVID-19, Technology, Northwestern Memorial Hospital, Rufus Herve Bacote, Severe acute respiratory syndrome coronavirus 2, Brain, Northwestern Medicine, CIRI, Neurodegeneration, Multiple sclerosis, Neuro, Pharmaceutical industry, Vaccine, Medical imaging, W-ENV and COVID-19, GeNeuro, W-ENV AND COVID-19, GENEURO

Northwestern University is a pioneer in the comprehensive treatment of long-haul COVID-19 symptomatology, having established a Neuro COVID-19 Clinic at Northwestern Memorial Hospital as early as May 2020.

Key Points: 
  • Northwestern University is a pioneer in the comprehensive treatment of long-haul COVID-19 symptomatology, having established a Neuro COVID-19 Clinic at Northwestern Memorial Hospital as early as May 2020.
  • The purpose of the research agreement is to establish evidence of W-ENV expression on the transcriptional and protein level, to ascertain whether this protein can be a blood biomarker of neurological complications of long-haul COVID.
  • This research agreement complements the previously announced efforts in the long-haul COVID field that GeNeuro has launched in Europe with Fondation FondaMental and the CIRI (International Center for Infectiology Research, Lyon, France).
  • GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.